Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 81-86

  Metro, Giulio ^a   Chiari, Rita ^a   Duranti, Simona ^a   Siggillino, Annamaria ^a   Fischer, Matthias J ^a   Giannarelli, Diana ^b   Ludovini, Vienna ^a   Bennati, Chiara ^a   Marcomigni, Luca ^a   Baldi, Alice ^a   Giansanti, Michele ^a   Minotti, Vincenzo ^a   Crinò, Lucio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

EGFR; EGFR TKI; Erlotinib; Gefitinib; KRAS; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GENOMIC DNA;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84866147012     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.06.005     Document Type: Article

References (35)

1. Huang S.M., Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999, 17:259-269.
2. Metro G., Finocchiaro G., Toschi L., Bartolini S., Magrini E., Cancellieri A., et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials 2006, 1:1-13.
3. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
4. Metro G., Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 2012, 1:5-13.
5. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
6. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
7. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
8. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
9. Riely G.J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:201-205.
10. Danenberg K.D., Grimminger P.P., Mack P.C., Danenberg P.V., Cooc J., Stephens C., et al. KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): implications for cetuximab therapy. J Clin Oncol 2010, 28(Suppl. 15):10529. [abstract].
11. Mao C., Qiu L.X., Liao R.Y., Du F.B., Ding H., Yang W.C., et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010, 69:272-278.
12. Tiseo M., Rossi G., Capelletti M., Sartori G., Spiritelli E., Marchioni A., et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 2010, 67:355-360.
13. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13:2890-2896.
14. Schneider C.P., Heigener D., Schott-von-Römer K., Gütz S., Laack E., Digel W., et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008, 3:1446-1453.
15. Pirker R., Su W., Rooneem R., Mehic B., Franke F. Clinical outcomes with erlotinib in relation to biomarker status: analyses from the open-label TRUST study in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2008, 19(Suppl. 8):265P. [abstract].
16. Marchetti A., Milella M., Felicioni L., Cappuzzo F., Irtelli L., Del Grammastro M., et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009, 11:1084-1092.
17. Ludovini V., Bianconi F., Pistola L., Chiari R., Minotti V., Colella R., et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:707-715.
18. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18:752-760.
19. Miller V.A., Riely G.J., Zakowski M.F., Li A.R., Patel J.D., Heelan R.T., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26:1472-1478.
20. Felip E., Rojo F., Reck M., Heller A., Klughammer B., Sala G., et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008, 14:3867-3874.
21. Zucali P.A., Ruiz M.G., Giovannetti E., Destro A., Varella-Garcia M., Floor K., et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008, 19:1605-1612.
22. Jackman D.M., Miller V.A., Cioffredi L.A., Yeap B.Y., Jänne P.A., Riely G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15:5267-5273.
23. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
24. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005, 40:90-97.
25. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
26. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
27. Jänne P.A., Wang X., Socinski M.A., Crawford J., Stinchcombe T.E., Gu L., et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 Trial. J Clin Oncol 2012, 30:2063-2069.
28. Yoshioka H., Hotta K., Kiura K., Takigawa N., Hayashi H., Harita S., et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J Thorac Oncol 2010, 5:99-104.
29. Ihle N.T., Byers L.A., Kim E.S., Saintigny P., Lee J.J., Blumenschein G.R., et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012, 104:228-239.
30. Garassino M.C., Marabese M., Rusconi P., Rulli E., Martelli O., Farina G., et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 2011, 22:235-237.
31. Chang M.H., Ahn H.K., Lee J., Jung C.K., Choi Y.L., Park Y.H., et al. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer 2011, 117:143-151.
32. Wang F., Wang J., Bai H., Zhao J., Wang Z., Zhuo M., et al. An evaluation of phosphorylated EGFR expression in predicting outcome of EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type. J Clin Oncol 2011, 29(Suppl.):7532. [abstract].
33. Riely G.J., Kris M.G., Rosenbaum D., Marks J., Li A., Chitale D.A., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734.
34. Janne P.A., Shaw A.T., Rodrigues Pereira J., Jeannin G., Vansteenkiste J., Barrios C.H., et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30(Suppl.):7503. [abstract].
35. Riely G.J., Brahmer J.R., Planchard D., Crinò L., Doebele R.C., Mas Lopez L.A., et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. J Clin Oncol 2012, 30(Suppl.):7531. [abstract].